Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
23 Pt 1
|
pubmed:dateCreated |
1991-12-16
|
pubmed:abstractText |
In order to understand the cellular events associated with cell death after the formation of topoisomerase II-DNA cleavable complexes, we compared the induction of endonucleolytic DNA fragmentation by etoposide and its more potent analog, teniposide (VM-26) in the human cell lines HT-29 and HL-60. A new filter-binding assay is described, which allows rapid quantification of nonprotein-linked DNA fragmentation involved in apoptosis. Both cell lines showed similar loss of colony formation ability following 30 min of treatment with various VM-26 concentrations even though the initial topoisomerase II-mediated DNA single-strand break frequency was higher in HL-60 cells. DNA repair studies following drug removal indicated that VM-26-induced DNA breaks reversed rapidly and completely in HT-29 cells, while in HL-60 cells, the initial lesions persisted at and above 5 microM VM-26. In both cell lines, topoisomerase II cleavage complexes, as measured by DNA-protein cross-links by alkaline elution, reversed rapidly and completely within 2-3 h. Secondary DNA fragmentation resembling chromatin endonucleolytic cleavage by apoptosis could be detected in HL-60 cells 3 h after VM-26 or etoposide treatment but not in HT-29 cells. Secondary DNA fragmentation was also induced in the human colon cancer cell lines COLO 320, which have c-myc amplification. Since HL-60 cells also have c-myc amplification and HT-29 do not, it is possible that c-myc overexpression may be involved in secondary DNA fragmentation. Finally, our results indicate heterogeneity of cell death mechanisms after exposure to topoisomerase II inhibitors among human cancer cell lines.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
51
|
pubmed:geneSymbol |
c-myc
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
6280-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1933888-Adenocarcinoma,
pubmed-meshheading:1933888-Colonic Neoplasms,
pubmed-meshheading:1933888-DNA, Neoplasm,
pubmed-meshheading:1933888-DNA Damage,
pubmed-meshheading:1933888-DNA Repair,
pubmed-meshheading:1933888-Etoposide,
pubmed-meshheading:1933888-Gene Amplification,
pubmed-meshheading:1933888-Genes, myc,
pubmed-meshheading:1933888-Humans,
pubmed-meshheading:1933888-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:1933888-Teniposide,
pubmed-meshheading:1933888-Tumor Cells, Cultured,
pubmed-meshheading:1933888-Tumor Stem Cell Assay
|
pubmed:year |
1991
|
pubmed:articleTitle |
Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
|
pubmed:affiliation |
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|